SAR421869
Total Payments
$223,460
Transactions
21
Doctors
0
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $116,702 | 8 | 0 |
| 2018 | $300.00 | 3 | 0 |
| 2017 | $106,459 | 10 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $223,460 | 21 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat in Patients With Usher Syndrome Type 1B | SANOFI US SERVICES INC. | $80,497 | 0 |
| An Open-Label Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat in Patients With Usher Syndrome Type 1B | SANOFI US SERVICES INC. | $48,262 | 0 |
| A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected SAR421869, Administered to Patients With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B | SANOFI US SERVICES INC. | $33,568 | 0 |
| An Open-Label Study to Determine the Long-Term Safety, Tolerability and Biological,Activity of UshStat? in Patients with Usher Syndrome type 1B | SANOFI US SERVICES INC. | $25,868 | 0 |
| A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected UshStat, Adminstered to Patients With Retinitis Pigmentosa Associated with Usher Syndrome Type 1B | SANOFI US SERVICES INC. | $20,750 | 0 |
| An Open-Label Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat in Patients With Usher Syndrome Type 1B | GENZYME CORPORATION | $14,516 | 0 |
Top Doctors Receiving Payments for SAR421869
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Ocala, FL | $223,460 | 21 |
Ad
Manufacturing Companies
- SANOFI US SERVICES INC. $208,945
- GENZYME CORPORATION $14,516
Product Information
- Type Drug
- Total Payments $223,460
- Total Doctors 0
- Transactions 21
About SAR421869
SAR421869 is a drug associated with $223,460 in payments to 0 healthcare providers, recorded across 21 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI US SERVICES INC..
Payment data is available from 2017 to 2019. In 2019, $116,702 was paid across 8 transactions to 0 doctors.
The most common payment nature for SAR421869 is "Unspecified" ($223,460, 100.0% of total).
SAR421869 is associated with 6 research studies, including "A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat in Patients With Usher Syndrome Type 1B" ($80,497).